home / stock / imgn / imgn quote
Last: | $31.23 |
---|---|
Change Percent: | 0.0% |
Open: | $0 |
Close: | $31.23 |
High: | $0 |
Low: | $0 |
Volume: | 538 |
Last Trade Date Time: | 12/31/1969 07:00:00 pm |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$31.23 | $0 | $31.23 | $0 | $0 | 538 | 03-12-2024 |
$31.23 | $0 | $31.23 | $0 | $0 | 538 | 03-11-2024 |
$31.23 | $0 | $31.23 | $0 | $0 | 40 | 02-26-2024 |
$31.23 | $31.24 | $31.23 | $31.25 | $31.22 | 48,606,862 | 02-09-2024 |
$31.23 | $31.23 | $31.23 | $31.24 | $31.22 | 49,305,516 | 02-08-2024 |
$29.55 | $29.5 | $29.55 | $29.69 | $29.41 | 10,516,456 | 02-07-2024 |
$29.51 | $29.31 | $29.51 | $29.55 | $29.25 | 8,601,393 | 02-06-2024 |
$29.3 | $29.26 | $29.3 | $29.39 | $29.24 | 4,856,528 | 02-05-2024 |
$29.26 | $29.36 | $29.26 | $29.47 | $29.21 | 6,353,946 | 02-02-2024 |
$29.36 | $29.35 | $29.36 | $29.48 | $29.26 | 3,116,474 | 02-01-2024 |
$29.32 | $29.53 | $29.32 | $29.6 | $29.15 | 6,266,296 | 01-31-2024 |
$29.39 | $29.48 | $29.39 | $29.54 | $29.37 | 3,917,986 | 01-30-2024 |
$29.42 | $29.57 | $29.42 | $29.62 | $29.35 | 3,987,568 | 01-29-2024 |
$29.57 | $29.53 | $29.57 | $29.57 | $29.49 | 2,691,682 | 01-26-2024 |
$29.5 | $29.56 | $29.5 | $29.575 | $29.49 | 4,429,838 | 01-25-2024 |
$29.5 | $29.5 | $29.5 | $29.54 | $29.42 | 2,976,802 | 01-24-2024 |
$29.44 | $29.59 | $29.44 | $29.59 | $29.44 | 6,151,165 | 01-23-2024 |
$29.54 | $29.53 | $29.54 | $29.62 | $29.515 | 5,117,966 | 01-22-2024 |
$29.52 | $29.58 | $29.52 | $29.605 | $29.51 | 3,434,412 | 01-19-2024 |
$29.53 | $29.63 | $29.53 | $29.63 | $29.51 | 4,538,838 | 01-18-2024 |
News, Short Squeeze, Breakout and More Instantly...
Klepierre (KLPEF) is expected to report for Q4 2023 comScore Inc. (SCOR) is expected to report $0.8 for Q4 2023 Universal Stainless & Alloy Products Inc. (USAP) is expected to report for Q4 2023 FAT Brands Inc. (FAT) is expected to report $-1.55 for Q4 2023 Jet.AI Inc. (JTAI) ...
AbbVie Completes Acquisition of ImmunoGen PR Newswire Adds flagship antibody-drug conjugate (ADC) ELAHERE ® (mirvetuximab soravtansine-gynx) for folate receptor-alpha (FRα) positive platinum-resistant ovarian cancer (PROC) to AbbVie's portfolio ...
2024-02-10 09:34:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...